FGEN

FibroGen, Inc. (FGEN) | Rumor.io

FibroGen

FGEN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)90%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about FGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Dec 15

FibroGen, Inc. ($FGEN) received FDA Orphan Drug Designation for its drug roxadustat to treat myelodysplastic syndromes (MDS), granting development incentives and 7 years of U.S. market exclusivity.
Roxadustat showed improved transfusion independence versus placebo in patients with high transfusion burden in the Phase 3 MATTERHORN trial, and the company plans to finalize its Phase 3 protocol for FDA submission in Q4 2025.
FibroGen has a cash-rich balance sheet with $120+M, following the sale of its China rights to AstraZeneca for $220M, and the stock is expected to run higher due to multiple catalysts.

Generated by AI

Sentiment

Of the messages about FGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	40% -60	83.66% +3.78
Bearish	—	100%	60% new	16.34% -3.78

Bullish· Dec 15

The company has received FDA orphan designation, which could lead to a significant increase in value, with some expecting at least 100% growth from current levels.
The sale of FibroGen China to AstraZeneca for $220 million has provided the company with a cash reserve of over $120 million, setting it up for a potential "runaway" period until 2028.
The stock has shown a strong upward trend, with some analysts predicting a move to $25 or higher, and others setting stop-loss points above $8, indicating a high level of confidence in the stock's potential for growth.

Bearish· Feb 25

The company's decision to sell its China operations for a low amount to Astrazenica, followed by an at-the-market (ATM) offering, has led to significant dilution of shareholder value.
The company's cash hoard is likely to be depleted to fund research and development activities, potentially requiring new offerings to stay afloat, and may not be enough to get the drug approved and marketed in the US.
The company's recent actions, including the ATM offering and the sale of its China operations, suggest a lack of transparency and potential mismanagement, leading to a loss of investor trust.

Generated by AI

Topics

Of the messages about FGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	5.9%
Macro	—	—	13.89%	6.96%
Earnings	—	—	0%	12.86%
Controversies	—	—	25%	2.42%
Announcements	—	—	61.11%	60.82%
Analysts	—	—	0%	11.04%

Earnings· Aug 7

FibroGen, Inc. (FGEN) beats earnings estimates by $0.31 and revenue estimates by $13.36M.
The company reports FQ2 earnings of -28c EPS and $43.95M in revenue.
FibroGen beats Estimize EPS and revenue consensus estimates, with a 29c beat on EPS and a $13.36M beat on revenue.

Analysts· Jul 16

B of A Securities downgraded FibroGen to Neutral with a $29 price target due to limited PO upside and lack of catalysts.
Stifel analyst Annabel Samimy downgraded FibroGen from Buy to Hold and lowered the price target from $55 to $29.
Mizuho lowered FibroGen's price target to $18.00 with a neutral rating, while Cowen downgraded it to Hold with a price target of $29.

Announcements· Dec 15

FibroGen's (FGEN) roxadustat received FDA Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS), granting development incentives and seven years of U.S. market exclusivity upon approval.
The designation highlights a significant unmet need, as current therapies leave many low-risk MDS patients transfusion-dependent, with roxadustat showing improved transfusion independence versus placebo in patients with high transfusion burden in a post-hoc analysis.
FibroGen plans to finalize its Phase 3 protocol for FDA submission in the fourth quarter of 2025, with oral administration potentially differentiating the drug from existing second-line options.

Controversies· Apr 8

Multiple law firms are investigating potential securities fraud claims against FibroGen, Inc. (FGEN) related to manipulated drug data and inaccurate business statements.
Several law firms have announced investigations into FGEN, including Scott+Scott Attorneys at Law LLP, Ademi LLP, and Levi & Korsinsky, LLP, on behalf of investors who may have suffered losses.
The investigations are centered around alleged securities fraud violations by FGEN officers and directors, including claims of manipulating drug data and making inaccurate statements about the company's business operations and prospects.

Technical Analysis· Feb 20

$FGEN is currently in a gap down and is above recent resistance, potentially moving to $1.60 if it becomes support.
$FGEN has not crossed the entry indicator at $0.87, but the team has capitalized on $WOK momentum and is monitoring conditions for adjustments.
A break above $0.90 could lead to $FGEN reaching $1+ by close, with huge limit orders on the ask side and increasing number of shares available to short.

Generated by AI

Community

Of the messages about FGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	72.58%	55.12%
Newcomers	0%	0%	27.42%	44.88%

Regulars· Jun 4

FibroGen, Inc. ($FGEN) has announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate its immuno-oncology assets.
$FGEN's stock price has experienced significant fluctuations, with a 10.76% drop to $1.41 in the last 18 minutes, and a 12.06% increase to $1.58 in the last 20 minutes.
FibroGen's clinical milestones include a Phase 2/3 study in metastatic pancreatic cancer in mid-2024 and a Phase 3 study in locally advanced unresectable pancreatic cancer in the 3rd Q of 2024.

Newcomers· Dec 15

The FDA has granted Orphan Drug Designation to FibroGen's roxadustat for the treatment of myelodysplastic syndromes, which could lead to reduced regulatory fees and increased market value.
FibroGen has a strong financial position, with over $120 million in cash and a recent sale of its China operations to AstraZeneca for $220 million, which could fuel future growth and development.
The company's CEO has added to their shareholdings, and some analysts believe that FibroGen's stock could see significant gains, with some predicting a 100% increase in value from current levels.

Generated by AI

Also Discussed

Investors talking about FGEN also mention

#	Name	Attention
1	Akebia Therapeutics Inc.AKBA	0.01%+0
2	BPMC - Blueprint Medicines Corporation	——
3	BLCM - Bellicum Pharmaceuticals, Inc.	——
4	Xencor Inc.XNCR	0%new
5	MBT - Mobile TeleSystems Public Joint Stock Company	——
6	WisdomTree Global ex-U.S. Quality Dividend Growth FundDNL	0%new
7	Direxion Daily MSCI Emerging Markets Bull 3X SharesEDC	0%0
8	Five Point Holdings LLC Class A Common SharesFPH	0%new
9	Alico Inc.ALCO	0%0
10	AC - Associated Capital Group, Inc.	——

FibroGen, Inc.

Location

Social

What share of all stock conversation is about FGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Dec 15

FibroGen, Inc. ($FGEN) received FDA Orphan Drug Designation for its drug roxadustat to treat myelodysplastic syndromes (MDS), granting development incentives and 7 years of U.S. market exclusivity.
Roxadustat showed improved transfusion independence versus placebo in patients with high transfusion burden in the Phase 3 MATTERHORN trial, and the company plans to finalize its Phase 3 protocol for FDA submission in Q4 2025.
FibroGen has a cash-rich balance sheet with $120+M, following the sale of its China rights to AstraZeneca for $220M, and the stock is expected to run higher due to multiple catalysts.

Generated by AI

Sentiment

Of the messages about FGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	40% -60	83.66% +3.78
Bearish	—	100%	60% new	16.34% -3.78

Bullish· Dec 15

The company has received FDA orphan designation, which could lead to a significant increase in value, with some expecting at least 100% growth from current levels.
The sale of FibroGen China to AstraZeneca for $220 million has provided the company with a cash reserve of over $120 million, setting it up for a potential "runaway" period until 2028.
The stock has shown a strong upward trend, with some analysts predicting a move to $25 or higher, and others setting stop-loss points above $8, indicating a high level of confidence in the stock's potential for growth.

Bearish· Feb 25

The company's decision to sell its China operations for a low amount to Astrazenica, followed by an at-the-market (ATM) offering, has led to significant dilution of shareholder value.
The company's cash hoard is likely to be depleted to fund research and development activities, potentially requiring new offerings to stay afloat, and may not be enough to get the drug approved and marketed in the US.
The company's recent actions, including the ATM offering and the sale of its China operations, suggest a lack of transparency and potential mismanagement, leading to a loss of investor trust.

Generated by AI

Topics

Of the messages about FGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	5.9%
Macro	—	—	13.89%	6.96%
Earnings	—	—	0%	12.86%
Controversies	—	—	25%	2.42%
Announcements	—	—	61.11%	60.82%
Analysts	—	—	0%	11.04%

Earnings· Aug 7

FibroGen, Inc. (FGEN) beats earnings estimates by $0.31 and revenue estimates by $13.36M.
The company reports FQ2 earnings of -28c EPS and $43.95M in revenue.
FibroGen beats Estimize EPS and revenue consensus estimates, with a 29c beat on EPS and a $13.36M beat on revenue.

Analysts· Jul 16

B of A Securities downgraded FibroGen to Neutral with a $29 price target due to limited PO upside and lack of catalysts.
Stifel analyst Annabel Samimy downgraded FibroGen from Buy to Hold and lowered the price target from $55 to $29.
Mizuho lowered FibroGen's price target to $18.00 with a neutral rating, while Cowen downgraded it to Hold with a price target of $29.

Announcements· Dec 15

FibroGen's (FGEN) roxadustat received FDA Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS), granting development incentives and seven years of U.S. market exclusivity upon approval.
The designation highlights a significant unmet need, as current therapies leave many low-risk MDS patients transfusion-dependent, with roxadustat showing improved transfusion independence versus placebo in patients with high transfusion burden in a post-hoc analysis.
FibroGen plans to finalize its Phase 3 protocol for FDA submission in the fourth quarter of 2025, with oral administration potentially differentiating the drug from existing second-line options.

Controversies· Apr 8

Multiple law firms are investigating potential securities fraud claims against FibroGen, Inc. (FGEN) related to manipulated drug data and inaccurate business statements.
Several law firms have announced investigations into FGEN, including Scott+Scott Attorneys at Law LLP, Ademi LLP, and Levi & Korsinsky, LLP, on behalf of investors who may have suffered losses.
The investigations are centered around alleged securities fraud violations by FGEN officers and directors, including claims of manipulating drug data and making inaccurate statements about the company's business operations and prospects.

Technical Analysis· Feb 20

$FGEN is currently in a gap down and is above recent resistance, potentially moving to $1.60 if it becomes support.
$FGEN has not crossed the entry indicator at $0.87, but the team has capitalized on $WOK momentum and is monitoring conditions for adjustments.
A break above $0.90 could lead to $FGEN reaching $1+ by close, with huge limit orders on the ask side and increasing number of shares available to short.

Generated by AI

Community

Of the messages about FGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	72.58%	55.12%
Newcomers	0%	0%	27.42%	44.88%

Regulars· Jun 4

FibroGen, Inc. ($FGEN) has announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate its immuno-oncology assets.
$FGEN's stock price has experienced significant fluctuations, with a 10.76% drop to $1.41 in the last 18 minutes, and a 12.06% increase to $1.58 in the last 20 minutes.
FibroGen's clinical milestones include a Phase 2/3 study in metastatic pancreatic cancer in mid-2024 and a Phase 3 study in locally advanced unresectable pancreatic cancer in the 3rd Q of 2024.

Newcomers· Dec 15

The FDA has granted Orphan Drug Designation to FibroGen's roxadustat for the treatment of myelodysplastic syndromes, which could lead to reduced regulatory fees and increased market value.
FibroGen has a strong financial position, with over $120 million in cash and a recent sale of its China operations to AstraZeneca for $220 million, which could fuel future growth and development.
The company's CEO has added to their shareholdings, and some analysts believe that FibroGen's stock could see significant gains, with some predicting a 100% increase in value from current levels.

Generated by AI

FibroGen

Social

Dec 15

Sentiment

Bullish· Dec 15

Bearish· Feb 25

Topics

Earnings· Aug 7

Analysts· Jul 16

Announcements· Dec 15

Controversies· Apr 8

Technical Analysis· Feb 20

Community

Regulars· Jun 4

Newcomers· Dec 15

Also Discussed

FibroGen, Inc.

Company Information

Location

Also Discussed

Social

Dec 15

Sentiment

Bullish· Dec 15

Bearish· Feb 25

Topics

Earnings· Aug 7

Analysts· Jul 16

Announcements· Dec 15

Controversies· Apr 8

Technical Analysis· Feb 20

Community

Regulars· Jun 4

Newcomers· Dec 15